Evidence map›Paper›PMID 41398603›Full record

ArticleWorld journal of surgical oncology2025

Semiquantitative immunohistochemical (IHC) pixelwise H-score of mitochondrial transcription factor A (TFAM) in gastric adenocarcinoma (GAC): clinicopathological significance and association with p53 and HER2.

Liang-Hung Ou, Hui-Ting Lee, Chia-I Lin, Yung-Hui Li, Wan-Chun Li, Chen-Sung Lin, Chiang-Ting Chien

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liang-Hung Ou *School of Life Science, National Taiwan Normal University, No. 88, Sec. 4, Ting-Zhou Rd., Wen-Shan Dist., Taipei 116, Taiwan.
Hui-Ting Lee *Division of Allergy, Immunology & Rheumatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, 104, Taiwan.
Chia-I LinDivision of Anatomy and Pathology, Taipei Hospital, Ministry of Health and Welfare, New Taipei City, 242, Taiwan.
Yung-Hui LiHon Hai Research Institute, Taipei, 114, Taiwan.ORCID http://orcid.org/0000-0002-0475-3689
Wan-Chun LiInstitute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.ORCID http://orcid.org/0000-0003-0481-4215
Chen-Sung LinDivision of Thoracic Surgery, Department of Surgery, Taipei Hospital, Ministry of Health and Welfare, No. 127, Si-Yuan Rd., Xin-Zhuang Dist., New Taipei City, 242, Taiwan. doc2765c@gmail.com.
Chiang-Ting ChienSchool of Life Science, National Taiwan Normal University, No. 88, Sec. 4, Ting-Zhou Rd., Wen-Shan Dist., Taipei 116, Taiwan. ctchien@ntnu.edu.tw.

Funding

Ministry of Health and Welfare, Taiwan, awarded to the affiliated Taipei Hospital 11003Ministry of Health and Welfare, Taiwan, awarded to the affiliated Taipei Hospital 11103Taipei Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan TH-202408
6 · The paper itself

Abstract

backgroundThe roles of p53 and HER2 in gastric adenocarcinoma (GAC) have been extensively studied; nevertheless, the contribution of mitochondrial transcription factor A (TFAM) remains unclear. Concerning TFAM's pivotal role in mitochondrial biogenesis, this study aimed to evaluate the TFAM expression in GAC and to assess its associations with p53 and HER2 expressions and clinicopathological outcomes.

methodsWe retrospectively analyzed 77 GAC patients who underwent upfront gastrectomy at Taipei Hospital between 2012 and 2021. Their clinicopathological profiles were recorded in detail. Immunohistochemical (IHC) staining for TFAM, p53, and HER2 protein expressions was semiquantified using IHC pixelwise H-score analyzed by ImageJ plugins IHC profiler. Associations between two continuous variables were assessed by Spearman's correlation coefficient (CC), and trendlines were fitted using SPSS's curve estimation function. The optimal cutoff for survival discrimination was derived from receiver operating characteristic (ROC) curve analysis by selecting the threshold with the highest Youden index and area under the curve (AUC). Prognostic variables with a Log-rank test p-value ≤ 0.1 were entered into a multi-variate Cox proportional hazards regression (Cox regression) model to identify independent ones and their relative hazards ratio (HR).

resultsTFAM IHC pixelwise H-score was significantly associated with advanced T and N status, lymphovascular invasion, perineural invasion and poor differentiation (all's p < 0.05), and was inversely correlated with tumor size (Spearman's rho CC = -0.402, p < 0.001) in a logarithmic distribution (p < 0.001). A positive correlation (Spearman's rho CC = 0.312, p = 0.006) in cubic distribution (p < 0.001) was observed between p53and TFAM IHC pixelwise H-scores. ROC analysis yielded a TFAM IHC pixelwise H-score cutoff of 43.0 (AUC = 0.650, 95%CI = 0.515-0.785, p = 0.047; sensitivity = 0.490, specificity = 0.810) to dichotomize high and low groups. In multi-variate Cox regression, low TFAM IHC pixelwise H-score (HR = 2.332, 95%CI = 1.136-4.787, p = 0.021), M1 status (HR = 3.582, 95%CI = 1.608-7.979, p = 0.002), and perineural invasion (HR = 4.506, 95%CI = 1.541-13.177, p = 0.006) were identified as independent variables to poor prognosis with elevated HRs. Among patients with high TFAM expression, higher HER2 IHC pixelwise H-score was associated with elevated hazard (HR = 1.010, 95%CI = 1.002-1.019, p = 0.020, Cox regression, uni-variate). Among M1 patients, higher p53 IHC pixelwise H-score was related to elevated hazard (HR = 1.029, 95%CI = 1.004-1.056, p = 0.025, Cox regression, uni-variate).

conclusionsROC and multi-variate Cox regression identified low TFAM expression as an independent poor prognostic variable for operable GAC patients, implying its potential as a quantitative prognostic biomarker. The observed associations with p53 and HER2 are hypothesis-generating and they require further validation to clarify TFAM's role in Warburg effect and GAC progression.

Indexed as

AdenocarcinomaBiomarkers, TumorDNA-Binding ProteinsErb-b2 Receptor Tyrosine KinasesMitochondrial ProteinsStomach NeoplasmsTranscription FactorsTumor Suppressor Protein p53AdultAgedFemaleFollow-Up StudiesGastrectomyHumansImmunohistochemistryMaleBiomarkers, TumorDNA-Binding ProteinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMitochondrial ProteinsTFAM protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53Gastric adenocarcinoma (GAC)HER2Mitochondrial transcription factor A (TFAM)p53Warburg effect

Identifiers

PMID41398603
PMCPMC12707001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.